Floatz logo

Saroglitazar

Metabolic Dysfunction-Associated Steatotic Liver Disease

Zydus Lifesciences LimitedSmall moleculePhase 4 / ApprovedActive
BB
70/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
63/ 100
Competitive Position
81/ 100

Competitive context

130 Active assets in the Metabolic Dysfunction-Associated Steatotic Liver Disease cohort.

Asset / SponsorPhaseRating
Dapagliflozin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
Exenatide
Fudan University
Phase 4BBB
Metformin
Xiqiao Zhou
Phase 4BBB
Empagliflozin
Justin Ryder
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB

View all 50 →

Same molecule, other indications

Saroglitazar is also rated in:

primary biliary cholangitisActive
BB
Indicative · Phase 3
71 / 100
View asset →
metabolic dysfunction-associated steatohepatitisActive
BB
Indicative · Phase 2
66 / 100
View asset →
inherited lipid metabolism disorderActive
BB
Indicative · Phase 4
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →